Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma

Managed Care Interface

Volumn 17, Issue 9, 2004, Pages 52-61

  Mehta, Jayesh ^a,d   Duff, Steven B ^b   Gupta, Sanjay ^c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UK   (United States)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CODEINE; DEXAMETHASONE; ERYTHROPOIETIN; OPIATE; OXYCODONE; PAMIDRONIC ACID; THALIDOMIDE; ZOLEDRONIC ACID;

ADULT; ANEMIA; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFICACY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; HEALTH CARE COST; HUMAN; HYPERCALCEMIA; INFECTION; MALE; MULTIPLE MYELOMA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; RELAPSE; SPINAL CORD COMPRESSION; THROMBOCYTOPENIA;

BORONIC ACIDS; COST-BENEFIT ANALYSIS; DELPHI TECHNIQUE; ECONOMICS, PHARMACEUTICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 11144298117     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. San Miguel JF, Almeida J, Orfao A: Laboratory investigations, in Mehta J, Singhal S (eds): Myeloma. London, UK, Martin Dunitz. 2002.
2. Lokhorst H: Clinical features and diagnostic criteria, in Mehta J, Singhal S (eds): Myeloma. London, UK, Martin Dunitz, 2002.
3. Kyle RA, Gertz MA, Witzig TE, et al: Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
4. Joshua DE, Gibson J: Epidemiology of plasma cell disorders, in Mehta J, Singhal S (eds): Myeloma. London, UK, Martin Dunitz, 2002.
5. Child JA, Morgan GJ, Davies FE, et al: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883.
6. Attal M, Harousseau JL, Stoppa AM, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma: Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97.
7. Singhal S: Treatment of multiple myeloma. BMJ 2003;327:575-576.
8. Rajkumar SV, Gertz MA, Kyle RA, et al: Current therapy for multiple myeloma. Mayo Clin Proc 2002;77:813-822.
9. Oken MM: Standard treatment of multiple myeloma. Mayo Clin Proc 1994;69:781-786.
10. Singhal S Mehta J: Treatment of relapsed and refractory multiple myeloma. Curr Treat Options Oncol 2003;4:229-237.
11. Ludwig H, Fritz E: Supportive therapy, in Mehta J, Singhal S (eds): Myeloma. London, UK, Martin Dunitz, 2002.
12. Coward RA: The cost of chronic dialysis in multiple myeloma. Postgrad Med J 1989;65: 302-306.
13. Laakso M, Lahtinen R, Virkkunen P, et al: Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma: Finnish Leukaemia Group. Br J Haematol 1994;87:725-729.
14. Uyl-de Groot CA, Ossenkoppele GJ, van Riet AA, et al: The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma. Eur J Cancer 1994;30A:457-459.
15. Henon P, Donatini B, Eisenmann JC, et al: Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma. Bone Marrow Transplant 1995;16:19-25.
16. Duncan N, Hewetson M, Powles R, et al: An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma. Bone Marrow Transplant 1996; 18:1175-1178.
17. Jagannath S, Vesole DH, Zhang M, et al: Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant 1997;20:445-450.
18. Nord E, Wisloff F, Hjorth M, et al: Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma: Results from a randomised controlled trial. Pharmacoeconomics 1997;12:89-103.
19. Buijt I, Ossenkoppele GJ, Uyl-de Groot CA, et al: Costs of intensive treatment and follow-up of patients with multiple myeloma. Anticancer Drugs 1998;9:889-897.
20. Trippoli S, Messori A, Becagli P, et al: Treatments for newly diagnosed multiple myeloma: Analysis of survival data and cost-effectiveness evaluation. Oncol Rep 1998;5: 1475-1482.
21. Bruce NJ, McCloskey EV, Kanis JA, et al: Economic impact of using clodronate in the management of patients with multiple myeloma. Br J Haematol 1999;104:358-364.
22. Gessner U, Koeberle D, Thuerlimann B, et al: Economic analysis of terminal care for patients with malignant osteolytic bone disease and pain treated with pamidronate. Support Care Cancer 2000;8:115-122.
23. Coyte PC, Dobrow MJ, Broadfield L: Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma. Pharmacoeconomics 2001;19:845-854.
24. Sampson FC, Beard SM, Scott F, et al: Cost-effectiveness of high-dose chemotherapy in first-line treatment of advanced multiple myeloma. Br J Haematol 2001;113:1015-1019.
25. Gulbrandsen N, Wisloff F, Nord E, et al: Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma. Eur J Haematol 2001;66:328-336.
26. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-1571.
27. Barlogie B, Desikan R, Eddlemon P, et al: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98:492-494.
28. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348: 2609-2617
29. Juliusson G, Celsing F, Turesson I, et al: Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol 2000;109:89-96.
30. Kneller A, Raanani P, Hardan I, et al: Therapy with thalidomide in refractory multiple myeloma patients: The revival of an old drug. Br J Haematol 2000;108:391-393.
31. Blade J, Esteve J, Rosinol L, et al: Thalidomide in refractory and relapsing multiple myeloma. Semin Oncol 2001;28:588-592.
32. Hus M, Dmoszynska A, Soroka-Wojtaszko M, et al: Thalidomide treatment of resistant or relapsed multiple myeloma patients. Haematologica 2001;86:404-408.
33. Yakoub-Agha I, Attal M, Dumontet C, et al: Thalidomide in patients with advanced multiple myeloma: A study of 83 patients - report of the Intergroupe Francophone du Myelome (IFM). Hematol J 2002;3:185-192.
34. Grover JK, Uppal G, Raina V: The adverse effects of thalidomide in relapsed and refractory patients of multiple myeloma. Ann Oncol 2002; 13:1636-1640.
35. Tosi P, Zamagni E, Cellini C, et al: Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. Haematologica 2002;87:408-414.
36. Neben K, Moehler T, Benner A, et al: Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002;8:3377-3382.
37. Medicare: Physician fee schedule (2003 CY); Payment policies and relative value unit adjustments. Federal Register 2002;67:79965-80184.
38. Medicare: Hospital outpatient prospective payment system (2003 CY). Federal Register 2002;67:66717-67046.
39. Clinical Laboratory Fee Schedule. Baltimore, Centers for Medicare & Medicaid Services, 2002.
40. Medicare: Hospital inpatient prospective payment systems and FY 2003 rates. Federal Register 2002;67:49981-50289.
41. Drug Topics Redbook. Montvale, NJ, Thompson, June 2003.
42. Drug Topics Redbook. Montvale, NJ, Thompson, December 2003.
43. Laupacis A, Feeny D, Detsky AS, et al: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-481.
44. Gafni A, Birch S: Guidelines for the adoption of new technologies: A prescription for uncontrolled growth in expenditures and how to avoid the problem. CMAJ 1993;148: 913-917.
45. Garber AM, Weinstein MC, Torrance GW, et al: Theoretical foundations of cost-effectiveness analysis, in Gold MR, Siegel JE, Russell LB, et al (eds): Cost-Effectiveness in Health and Medicine. New York City, Oxford University Press, 1996.
46. Weinstein MC: From cost-effectiveness ratios to resource allocation: Where to draw the line? in Sloan FA (ed): Valuing Health Care. Cambridge, UK, Cambridge University Press, 1995.
47. Hsiao WC, Braun P, Dunn D, et al: Resource-based relative values: An overview. JAMA 1988;260:2347-2353.
48. Brown B: Delphi Process - A Methodology Used for the Evaluation of Opinions of Experts. Santa Monica, CA, The Rand Corporation, September 1968.